Bordeaux

• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Ended
  2023-505627-30-00 7 2023-07-26 Solid Neoplasm
• An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa Ended
  2022-502921-16-00 6 2023-07-21 Hemophilia A and B
• CC-122 Rollover Study Ended
  2022-501855-97-00 3 2023-06-29 Multiple Myeloma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma.
• OPTI-TREX - Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients Ended
  2024-513650-30-00 5 2023-06-28 Allograft vascular thrombosis
• A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects Wi … Ended
  2022-501618-70-00 7 2023-06-27 BRAF-V600 Mutant Solid Tumors including Melanoma, Non-small cell lung
• A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly … Ended
  2022-500275-31-00 5 2023-06-20 Haemophilia A
• ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended
  2022-501802-36-00 5 2023-06-16 Prevention of cardiac surgery associated acute kidney injury
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa
• Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended
  2022-500694-14-00 7 2023-06-02 Head and Neck Squamous Cell Cancer
• A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line met … Ended
  2023-506385-30-00 9 2023-05-22 Advanced Urothelial Carcinoma
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer
• Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended
  2022-501585-22-00 5 2023-05-11 Atopic Dermatitis
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)
• This is a phase 2, randomized, double blind, multicenter study evaluating the efficacy and safety of the combination of methotrexate plus UV … Ended
  2024-512766-34-00 4 2023-04-28 Vitiligo with new lesions or extension of old lesions during the last
• A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children … Ended
  2024-515552-21-00 3 2023-04-17 Recurrent or refractory neuroblastoma.
• A phase I of TG6050 in the treatment of patients with metastatic lung cancer Ended
  2024-513093-22-00 1 2023-03-27 Non-small cell lung cancer (NSCLC)
• A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patien … Ended
  2022-501363-40-00 3 2023-03-17 Advanced or metastatic solid tumors with a KRAS-G12C mutation
• OMX-0407 Phase I Study Ended
  2024-514554-75-00 1 2023-03-16 Previously treated unresectable solid tumours
• A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects with Metastatic Solid Tumors Ended
  2023-508529-29-00 9 2023-03-08 Metastatic Solid Malignant tumors
• A study to evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of treatment in children and adolescents with ASD Ended
  2024-512202-25-00 4 2023-02-27 Irritability associated with autistic disorder in children and adolesc
• A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509783-23-00 4 2023-02-24 Diffuse Cutaneous Systemic Sclerosis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effe … Ended
  2023-510317-26-00 4 2023-02-07 Amyotrophic Lateral Sclerosis
• A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Ended
  2022-500391-62-00 9 2023-01-19 Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL

Showing 937–960 of 1,109 trials